Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Contacts
location
Website URL
Legal Names
Legal name
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 20.02.2024. Their latest investor Science Creates Ventures. Their latest round Seed
Broadview Ventures
Broadview Ventures invests in technology solutions for cardiovascular and neurovascular diseases.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Science Creates Ventures
Science Creates Ventures is a Bristol-based venture capital firm that invests in early-stage deep tech companies.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
Co-Investors
Investors3
Number of lead investors
Number of investors
Science Creates Ventures
Science Creates Ventures is a Bristol-based venture capital firm that invests in early-stage deep tech companies.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
Harry Destecroix
Harry Destecroix is the Co-Founder and Managing Partner of Science Creates Ventures. He previously worked at Ziylo Ltd as a CEO & Co-Founder. Harry Destecroix attended the University of Bristol.
current job
count Of Investments
Broadview Ventures
Broadview Ventures invests in technology solutions for cardiovascular and neurovascular diseases.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Thomas Needham
Tom Needham, MBA, is a Director and Head of the Biopharmaceuticals practice at Broadview Ventures. Tom shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement. Tom comes to Broadview with 25 years of experience in venture capital, business development, corporate strategy, and executive management responsibilities in public and private life science companies. Prior to joining Broadview Ventures, Tom was most recently Chief Business Officer at Merrimack Pharmaceuticals (Nasdaq: MACK) and Senior Vice President, Business Development at C4 Therapeutics. Prior to C4T, Tom spent 13 years as a venture capital investor, most recently as a Managing Director at Synthesis Capital, where he was involved in the management of two healthcare venture funds focused on investments in biotechnology, pharmaceuticals and medical technology. Prior to Synthesis, Tom was a Principal at Advent International, a global private equity firm, as a member of the healthcare venture capital deal team in Boston. Earlier in his career, Tom held Vice President of Business Development positions at private and public biotech companies, including GPC Biotech (FSE: GPC/Nasdaq: GPCB) and Mitotix, Inc. (acquired by GPC Biotech), where he led the negotiation and closing of a number of strategic transactions, including industry partnerships with global pharmaceutical companies, R&D collaborations, licensing and M&A transactions. Tom holds a B.A. from Bowdoin College and an MBA from Babson College’s F.W. Olin Graduate School of Business. Tom currently holds board roles at Renovacor (Chairman), Basking Biosciences (Chairman), Antag Therapeutics, Kantum Pharma (Observer), and HAYA Therapeutics (Observer). Tom’s venture investment experience also includes working on Epirium Bio (fka Cardero Therapeutics), Astex Pharmaceuticals (Nasdaq: ASTX, acquired by Otsuka), Enanta Pharmaceuticals (Nasdaq: ENTA), MD Everywhere (acquired by Marlin Equity Partners), Sirion Therapeutics (trade sale to Alcon and Bausch & Lomb) and as an active deal team member on the IPO and exit from Aegerion Pharmaceuticals (Nasdaq: AEGR).
current job
Benjamin Kreitman
Benjamin Kreitman broadly supports the Broadview investment team in its day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement. Prior to joining Broadview, Benjamin was a Consultant at Monitor Deloitte, the strategy management consulting arm of Deloitte Consulting, LLP. At Monitor Deloitte, Benjamin worked alongside senior executives on a variety of engagements including commercial strategy development for biotechnology startups as well as global pharmaceutical and medical device manufacturers, and corporate development and investment due diligence across a number of industries. Benjamin earned undergraduate degrees in Biological Sciences and Financial Economics Magna Cum Laude from Columbia University.
current job
MEIF Proof-of-Concept & Early Stage Fund
MEIF Proof-of-Concept & Early Stage Fund invests in early-stage companies.
Sector
Subsector
Keywords
count Of Investments
Hannah Tapsell Chapman